'Clinical Cancer Research' Article States Tarvacin(TM) Equivalent Inhibits Tumor Growth by up to 90n Multiple Tumor Models Data Support Development of Tarvacin™ as Broad Spectrum Anti-Cancer Agent TUSTIN, Calif., March 7, 2005 /PRNewswire-FirstCall via COMTEX/ -- Peregrine Pharmaceuticals, Inc.
Affitech AS and Peregrine Pharmaceuticals Announce Research Milestone Achievement by Affitech TUSTIN, Calif., and OSLO, Norway, June 24 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) and Affitech AS today announced that they have achieved the first research milestone in
-- Career Development Award to Study Biology of Bavituximab and Chemotherapy in Lung Cancer Awarded to Dr. David Gerber of UT Southwestern Medical Center -
-- New Study Complements Ongoing Bavituximab Plus Carboplatin/Paclitaxel Phase II NSCLC Trial that has Shown Promising Preliminary Results -
Avanir And Peregrine Execute Commercial License Agreement For Anti-Cancer Antibody SAN DIEGO, Dec. 10 /PRNewswire-FirstCall/ -- Avanir Pharmaceuticals (Amex: AVN) announced today that a Commercial License Agreement with Peregrine Pharmaceuticals, Inc.
TUSTIN, Calif. , June 25, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology
Avid Bioservices and Bioreliance Team Up To Provide Eukaryotic Cell Banking Services to the Biopharmaceutical Industry Tustin, CA -September 20, 2005 - Avid Bioservices, Inc., a subsidiary of Peregrine Pharmaceuticals Inc. (PPHM), announced today that it has teamed up with BioReliance, Inc., a
Avid Bioservices and Halozyme Therapeutics Extend Commercial Manufacturing Agreement - Extended Terms May Include Up to 20 cGMP Runs per Year - TUSTIN, Calif., Dec. 19 /PRNewswire-FirstCall/ -- Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc.